



AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

Design and Evaluation of Fast Dissolving Oral Films of Granisetron Hydrochloride

Rawda Khalifa Ali*¹, A. R. Shabaraya¹, Mohd Azharuddin¹

1. Department of pharmaceutics, Srinivas college of pharmacy, Valachil, Mangalore, Karnataka, India

ABSTRACT

Granisetron hydrochloride is a novel serotonin 5-HT₃ receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. It is well absorbed from the gastrointestinal tract, but its oral bioavailability is low (60%) due to extensive first-pass metabolism which makes it an ideal candidate for rapid release drug delivery system. Hence, an attempt was made to prepare and evaluate fast dissolving oral films containing Granisetron hydrochloride as a model drug by solvent casting method using natural and synthetic polymers. Various formulations were developed with varying concentration of polymers like, CMC, HPMC and Pullulan. Citric acid was used as a disintegrating agent and Propylene glycol as a plasticizer. The prepared oral films were evaluated for their physicochemical and mechanical parameters such as Physical appearance, surface texture, Weight uniformity, surface pH, thickness uniformity, percentage moisture absorption, loss on drying, disintegration time, drug content uniformity, folding endurance, tensile strength, percentage elongation, *in-vitro* drug release, and stability studies. *In-vitro* release rate of Granisetron hydrochloride was studied in phosphate buffer pH 6.8. F7, F10 showed maximum release rate about 93.95% and 95.29% in 180 seconds respectively, whereas F3 showed 60.98%. The mechanism of drug release of fast dissolving oral film was found to be non-fickian diffusion following first order kinetics. The selected fast dissolving oral films were found to be superior to marketed conventional tablet. Short term stability studies of selected films indicated that there is no significant change with respect to physical appearance, disintegration time, drug content and *in-vitro* drug release.

Keywords: oral films, granisetron hydrochloride, HPMC, CMC, Pullulan

*Corresponding Author Email: rudi_333@hotmail.com

Received 18 October 2012, Accepted 28 October 2012

Please cite this article in press as Ali RK *et al.*, Design and Evaluation of Fast Dissolving Oral Films of Granisetron Hydrochloride. American Journal of PharmTech Research 2012.

INTRODUCTION

Fast-dissolving drug-delivery systems were first developed in the late 1970s as an alternative to tablets, capsules, and syrups for pediatric and geriatric patients who experience difficulties in swallowing traditional oral solid dosage forms.

For the past two decade, there has been an enhanced demand for more patient- friendly and compliant dosage forms. As a result, the demand for developing new technologies has been increasing annually¹. Since the development cost of a new drug molecule is very high, efforts are now being made by pharmaceutical companies to focus on the development of new drug dosage forms for existing drugs with improved safety and efficacy together with reduced dosing frequency, and the production of more cost effective dosage form².

Mouth dissolving films, a new drug delivery system for the oral delivery of the drugs, was developed based on the technology of the transdermal patch. The delivery system consists of a very thin oral strip, which is simply placed on the patient's tongue or any oral mucosal tissue, instantly wet by saliva the film rapidly hydrates and adheres onto the site of application. It then rapidly disintegrates and dissolves to release the medication for oral mucosal absorption or with formula modifications, will maintain the quick-dissolving aspects allow for gastrointestinal absorption to be achieved when swallowed⁵.

Among the different route of administration, the oral route of administration contains to be the most preferred route due to various advantageous including ease of administration, avoidance of pain, versatility, and most important is the patient compliance. One such relatively new dosage form is the oral strip^{1,2} Difficulty in swallowing (dysphagia) is a common problem of all groups, especially the elderly and pediatrics, because of physiological changes associated with these groups¹.

Cancer chemotherapy causes lot of adverse effects, of which nausea and vomiting is prime once. This can be clearly seen with model anticancer drug Cisplatin, which is first line drug in many types of cancers. Hence anti emetic drugs like Ondansetron, Granisetron are administered one hour prior to the administration of anticancer drug¹³.Granisetron HCl is a novel serotonin 5-HT₃ receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting centre in medulla oblongata.. Granisetron HCl is well absorbed from the gastrointestinal tract, but its oral bioavailability is low (60%) due to extensive first-pass metabolism. Since oral route by passes first- pass effect, the dose of

Granisetron hydrochloride could be reduced by 50%¹⁴.

Hence, an attempt was made to:

1. To design a fast dissolving oral film of Granisetron hydrochloride by solvent casting method.
2. To carry out drug and excipient compatibility studies by FTIR.
3. To perform various physiochemical and mechanical parameter of the prepared films.
4. To carry out *in-vitro* evaluation studies and to analyze the data with different kinetic models.
5. To perform the stability studies of the selected formulations as per the ICH guidelines.
6. To compare with the marketed dosage forms.

MATERIALS AND METHODS:

Granisetron hydrochloride was obtained as a gift sample from Sun pharma gujrat. CMC, and HPMC E-15 were procured from Yarrow chem products Mumbai, India, and pullulan was obtained as a gift sample from DKSH India private limited, Mumbai, India. Propylene glycol was obtained from Loba-chem, Mumbai, India. citric acid, menthol and vanillin were procured from Hi-media, Mumbai, India. Ethanol was obtained from KSBCL, Mandya, India. All the chemicals were of analytical grade.

Preparation of fast dissolving oral films of granisetron hydrochloride

Fast dissolving oral films of Granisetron hydrochloride was prepared by solvent casting method using polymers (CMC, HPMC, and pullulan). CMC polymer (250) mg was weighed accurately and it was soaked in half quantity of water for 8hr to get uniform dispersion. 10.6 mg of Granisetron hydrochloride was weighed and dissolved in water. Plasticizer (propylene glycol) was used in the range of 30% w/w of polymer concentration. This solution was added to the polymeric solution, and stirred well using a magnetic stirrer to obtain a homogenous solution, followed by the addition of vanillin and citric acid. Menthol was dissolved in 5ml of alcohol and added to the above solution and mixed well. The solution was allowed to stand for 30min to allow deaeration to take place. Solution was then casted in to a petri dish having area of 64cm² and 1.3cm wall height. Petri dish was kept in hot air oven for 12 hr at 50°C. After drying, films were removed with the help of sharp blade and kept in a desiccator for 24 hr before cutting in to small piece having area of 6cm². Films with air bubbles, cuts or imperfection were excluded from study.

Table 1: Composition of fast dissolving oral films of Granisetron hydrochloride

| | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 |
|------------------------------|-----|-----|-----|------|-----|-----|-----|------|-----|-----|------|------|
| Granisetron HCl | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CMC | 250 | 500 | 750 | 1000 | | | | | | | | |
| HPMC | | | | | 250 | 500 | 750 | 1000 | | | | |
| Pullulan | | | | | | | | | 500 | 750 | 1000 | 1250 |
| Propylene glycol% w/w | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Citricacid (mg) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Menthol(mg) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Vanillia(mg) | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 |
| Absolute alcohol | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s |
| water | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s | q.s |

Note: With the same procedure, various films were prepared by using various polymers (HPMC and pullulan) with different polymer concentration

Drug Excipient Compatibility Studies

FTIR can be used to investigate and predict any physicochemical interaction between different excipients. IR spectra matching approach was used for detection of any possible chemical interaction between the drug and polymer. A physical mixture of drug, polymers and other excipients were prepared and mixed with suitable quantity of potassium bromide. It was scanned from 4000 to 400 cm^{-1} in a FTIR spectrometer (FTIR 4100, Jasco). The IR spectrum of the physical mixture was compared with those of pure drug and polymer, and peak matching was done to detect any appearance or disappearance of peaks.



Figure1: Fast dissolving oral films of Granisetron hydrochloride

EVALUATION OF FAST DISSOLVING ORAL FILMS

Physical appearance and surface texture

This parameter was checked simply by visual inspection of films and evaluation of texture by feel or touch.

Weight uniformity of the film

The films were weighed individually using digital balance and average weight was calculated.

Surface pH

The films were allowed to swell in a closed petridish at room temperature for 30minutes in 10ml of phosphate buffer pH 6.8. Solution was placed under digital pH meter electrodes.

Thickness uniformity

Thickness of the film was measured using screw gauge with a least count of 0.01mm at different spots of the film. The thickness was measured at three different spots and average was calculated.

Percentage moisture absorption

The percentage moisture absorption test was carried out to ensure physical stability or integrity of films at high humid condition. The films were weighed and placed in a desiccator containing 100 ml of saturated solution of aluminum chloride and $75 \pm 5\%$ RH was maintained. After three days the films were taken out and reweighed. The percentage moisture absorption was calculated using the following formula.

$$\% \text{Moisture absorption} = \frac{\text{Final weight} - \text{Initial weight}}{\text{Initial weight}} \times 100$$

Percentage moisture loss

Percentage moisture loss was also carried to check the integrity of films at dry condition. It is determined by placing the prepared film in desiccators containing anhydrous calcium chloride. After three days, the film was taken and reweighed. The percent moisture loss was calculated using the following formula.

$$\% \text{Moisture loss} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

Loss on drying

The drying was carried out in an oven with a temperature above the temperature of solvent evaporation at atmospheric pressure. The LOD is the loss of mass expressed as percent (w/w). The weight of the films was measured until constant mass were achieved to ensure complete removal of residual solvent.

Folding endurance

The flexibility of a film can be measured quantitatively in terms of what is known as folding endurance. Folding endurance of the film was determined by repeatedly folding a small strip of

the film at the same place till it breaks. The number of times films could be folded at the same place, without breaking gives the value of folding endurance.

Tensile strength

Is the maximum stress (applied at one point) required for oral film to break. The film size 5 x 2cm² and free of physical imperfection was placed between two clamps held 10mm apart. The film was pulled by clamp at a rate of 5mm/min. It is calculated by the applied load at rupture divided by the cross sectional area of the strip as given in the equation below:

$$\text{Tensile strength} = \text{force at break} / \text{initial cross sectional area of film in mm}^2.$$

Percentage elongation

When stress is applied, a film sample stretches, and this is referred to as a strain. Strain is basically the deformation of film divided by the original dimension of the sample.

$$\text{Percentage elongation} = \text{Increase in length} / \text{original length} \times 100.$$

***In-vitro* disintegration time**

Disintegration time is defined as the time (second) at which a film starts to break when brought into contact with water or saliva. It provides an indication about the disintegration and dissolution characterization of the film. It can be determined by the following method:

Slide frame method: one drop of distilled water was dropped by a pipette onto the oral films. Therefore the films were clamped into slide frames and were placed planar on a Petri dish. The time until the film dissolved and caused a hole within the film was measured.

Drug content uniformity

Total drug content per film was estimated by random sampling of all the prepared formulations. Film of 6sq.cm was cut and placed in 50ml volumetric flask and dissolved in phosphate buffer 6.8. Then pipette out 1 ml of solution and dilute to 10ml with buffer. The absorbance of the solution was measured at 302nm.

***In-vitro* drug release**

In-vitro dissolution study was carried out using USP Basket type apparatus using 900ml of pH 6.8 phosphate buffer. The USP dissolution apparatus was thermostated at a temperature of 37±0.5 °C and stirred at rate of 50rpm. Aliquots of 5 ml were withdrawn at the time interval of every 30 seconds and replaced with equal volume of dissolution medium analyzed at 302nm by UV-VIS Spectrometer and cumulative amount of drug release at various time intervals were calculated.

KINETIC RELEASE STUDIES

Several theories/kinetic models describe drug dissolution from immediate and modified release

dosage form. In order to analyze the release mechanism, several release models were tested such as:

Zero order release Kinetic

To study the zero order release kinetics the release data was fitted into the following equation.

$$Q_t = Q_0 + K_0 t$$

Where 'Q_t' is the amount of drug released at time t, 'K₀' is the apparent dissolution rate constant or zero order release rate constant and 'Q₀' is the initial concentration of the drug in the solution resulting from a burst effect; in this case the drug release runs at a constant rate. The graph is plotted percentage cumulative drug release (%CDR) versus time.

First order Release Kinetic

To study the first order release kinetics the release rate data are fitted into the following equation.

$$\ln Q_t = \ln Q_0 + K_1 t$$

Where, k₁ is the first order release constant; in this case the drug released at each time is proportional to the residual drug inside the dosage form. The graph is plotted log %CDR remaining versus time.

Higuchi Release Model

To study the Higuchi release model the release rate data are fitted into the following equation.

$$Q_t = K_H \sqrt{t}$$

Where, 'Q_t' is the amount of drug released at time t, 'K_H' is the higuchi release rate constant; this is the most widely used model to describe drug release from pharmaceutical matrices. The graph plotted %CDR versus square root of time.

Korsmeyer and Peppas Kinetics

To study Korsmeyer and Peppas release kinetics the release rate data are fitted into following equation:

$$Q_t/Q_\infty = K_k t^n$$

Where K_k is a constant incorporating structural and geometric characteristic of the drug dosage form and n is the release exponent, indicative of the drug release mechanism. The graph is plotted log %CDR versus time.

The value of n=0.45 for Fickian (case I) release, >0.45 but <0.89 for non-fickian (Anomalous) release and 0.89 for case II (Zero order) release and >0.89 for super case II type of release. Case II transport generally refers to the dissolution of the polymeric matrix due to the

relaxation of the polymer chain and anomalous transport (Non fickian) refers to the summation of both diffusion and dissolution controlled release

Stability studies

Short term accelerated stability studies of the selected formulation were carried out. Best formulations were stored in an amber coloured bottle with aluminum cap as a closure. It was tightly sealed and kept in the incubator maintained at $40 \pm 2^\circ\text{C}$ and $75 \pm 5\%$ RH. The stability studies were carried out for 3 months. Samples were collected at 1month interval, it was observed for physical appearance, disintegration time, drug content and *in-vitro* drug release.

RESULT AND DISCUSSION

FTIR studies

The comparison of the IR spectrum revealed that there is no appreciable change in the positions of characteristic absorption bands of groups and bonds. The spectra of these, even though slightly differ in appearance but no change is observed in the positions of the bands in the spectra. This clearly suggests that the drug remains in the same form even in its formulations indicating that there is no interaction between the drug and polymer used for the study. The results are shown in Figure 2-5.




Figure 2: IR spectra of Granisetron hydrochloride




Figure 3: IR spectra of Granisetron hydrochloride and CMC




Figure 4: IR spectra of Granisetron hydrochloride and HPMC




Figure 5: IR spectra of Granisetron hydrochloride and Pullulan

Table 2: Various physicochemical properties of fast dissolving oral films of Granisetron hydrochloride

| Formulation code | Physical appearance | Surface texture | Weight uniformity (mg±SD) | Surface pH | Thickness (mm±SD) |
|------------------|---------------------|-----------------|---------------------------|------------|-------------------|
| F1 | Transparent | Very smooth | 34.1±0.072 | 6.67 | 0.0208±0.002 |
| F2 | Transparent | Very smooth | 46.2±0.057 | 6.80 | 0.145±0.004 |
| F3 | Transparent | Very smooth | 57.1±0.173 | 6.65 | 0.199±0.004 |
| F4 | Transparent | Very smooth | 63.4±0.11 | 6.76 | 0.283±0.003 |
| F5 | Transparent | Very smooth | 37.2±0.028 | 6.54 | 0.0214±0.003 |
| F6 | Transparent | Very smooth | 49.4±0.112 | 6.80 | 0.148±0.005 |
| F7 | Transparent | Very smooth | 60.1±0.129 | 6.53 | 0.205±0.005 |
| F8 | Transparent | Very smooth | 69.1±0.086 | 6.66 | 0.291±0.001 |
| F9 | Transparent | Very smooth | 55.2±0.072 | 6.59 | 0.154±0.002 |
| F10 | Transparent | Very smooth | 64.1±0.158 | 6.71 | 0.209±0.004 |
| F11 | Transparent | Very smooth | 73.1±0.086 | 6.74 | 0.250±0.003 |
| F12 | Transparent | Very smooth | 77.0±0.144 | 6.50 | 0.299±0.005 |

*All values represented are mean of 4 readings (n = 4)

Physical appearance and surface texture of film

The appearance of all the films were uniform having transparent in appearance The observation

suggests that the films were having smooth surface and they were elegant enough to see. The results are shown in Table 2. and it is shown in Figure 1.

Weight uniformity

As all batches do not have uniform amount of ingredient in it, hence their weight and thickness were varied. Weight uniformity of the films were found to be between 34.1 ± 0.072 mg to 77.0 ± 0.144 mg. The results are shown in Table 2

Thickness

Thickness of the films were found to be between 0.0208 ± 0.002 mm to 0.299 ± 0.005 mm. A very low standard deviation values indicates that the method used for the formulation of film is reproducible and give film of uniform thickness and hence dosage accuracy in each film can be ensured. The results are shown in Table 2.

Surface pH

Surface pH of all films were found to be in the range of 6.53 to 6.80. All films were found to be in the range of salivary pH. The results are shown in Table 2.

Percentage moisture loss and percentage moisture absorption

The study of percentage moisture loss and percentage moisture absorption gives the idea about the stability of the film in different environmental conditions. More the moisture absorption property of the film less stable it will be. However it was found that the % moisture absorption and percentage moisture loss increased with increase in hydrophilic polymers like HPMC, CMC and Pullulan. Percentage moisture loss was found to be between 1.23 to 3.91 and Percentage moisture absorption was found to be between 2.21 to 5.87. The results are shown in Table 3.

Disintegration time

The disintegrating time limit of 30 seconds or less for orally disintegrating tablets described in CDER guidance can be applied to fast dissolving oral films. Although, no official guidance is available for oral fast disintegrating film, this may be used as a qualitative guideline for quality control test or at development stage. Pharmacopoeial disintegrating time for films is 5-30 sec⁹. The *in-vitro* disintegration time of the films were found to be between 10 ± 0.31 to 58 ± 0.45 sec. Study showed that disintegration time was increased with increase in the polymer concentration. The results are represented in Table.No.3.

Drug content

Granisetron hydrochloride films prepared with various polymers were subjected to uniformity of drug content. The acceptance value of the preparation is less than 15% according to JPI5,

while in USP 27 , the content of preparation are between 85% and 115% and the relative standard deviation is less than or equal to 6.0. Drug content of the films was found to be between $97.62 \pm 0.011\%$ to $100.01 \pm 0.063\%$. The observed result indicate that the drug was uniformly dispersed throughout the film. The results are shown in Table 3.

Table 3: Percentage moisture loss, Percentage moisture absorption, disintegration time and drug content uniformity of all formulation

| Formulation code | % moisture loss | %moisture absorption | Disintegration time(sec \pm SD) | Drug content (% \pm SD) |
|------------------|-----------------|----------------------|-----------------------------------|---------------------------|
| F1 | 1.23 | 2.61 | 12 \pm 0.28 | 97.62 \pm 0.011 |
| F2 | 1.85 | 3.48 | 18 \pm 0.34 | 98.04 \pm 0.022 |
| F3 | 2.63 | 4.98 | 26 \pm 0.39 | 98.86 \pm 0.034 |
| F4 | 2.95 | 5.01 | 48 \pm 0.45 | 99.63 \pm 0.005 |
| F5 | 1.45 | 2.21 | 10 \pm 0.31 | 98.12 \pm 0.011 |
| F6 | 1.67 | 4.41 | 16 \pm 0.35 | 98.65 \pm 0.005 |
| F7 | 2.69 | 4.99 | 28 \pm 0.42 | 99.86 \pm 0.034 |
| F8 | 3.11 | 2.45 | 50 \pm 0.47 | 100.01 \pm 0.063 |
| F9 | 1.98 | 3.99 | 18 \pm 0.30 | 97.94 \pm 0.022 |
| F10 | 3.01 | 4.87 | 22 \pm 0.36 | 98.13 \pm 0.017 |
| F11 | 3.26 | 5.18 | 44 \pm 0.37 | 98.99 \pm 0.005 |
| F12 | 3.91 | 5.87 | 58 \pm 0.45 | 99.71 \pm 0.005 |

Table 4: Mechanical Properties of Fast Dissolving Oral Films Of Granisetron Hydrochloride

| Formulation code | Folding endurance(\pm SD) | Tensile strength Kg/cm ² | Percentage elongation |
|------------------|------------------------------|-------------------------------------|-----------------------|
| F1 | 262 \pm 2 | 1.27 \pm 0.021 | 12.5 \pm 4 |
| F2 | 273 \pm 5 | 1.48 \pm 0.028 | 23.3 \pm 4 |
| F3 | 272 \pm 6 | 1.8 \pm 0.0330 | 28.6 \pm 6 |
| F4 | 281 \pm 3 | 2.3 \pm 0.0167 | 30.6 \pm 3 |
| F5 | 265 \pm 4 | 1.31 \pm 0.025 | 16.6 \pm 6 |
| F6 | 274 \pm 5 | 1.50 \pm 0.031 | 23.3 \pm 5 |
| F7 | 281 \pm 3 | 1.86 \pm 0.035 | 26.6 \pm 8 |
| F8 | 292 \pm 6 | 2.41 \pm 0.0168 | 33.0 \pm 5 |
| F9 | 275 \pm 5 | 1.55 \pm 0.035 | 14.4 \pm 5 |
| F10 | 284 \pm 6 | 1.71 \pm 0.032 | 24.7 \pm 6 |
| F11 | 293 \pm 3 | 2.23 \pm 0.145 | 29.6 \pm 4 |
| F12 | 301 \pm 2 | 2.45 \pm 0.0178 | 33.0 \pm 5 |

Mechanical properties of fast dissolving oral films of Granisetron hydrochloride:

Folding endurance

Folding endurance measurement gives an indication of brittleness of the film. The value depends on hydrophilic polymer as well as plasticizer concentrations used. Folding endurance test result indicated that the film would not break and would maintain their integrity. Folding endurance for all the formulation was found to be more than 200 which was satisfactory to

reveal good film property Folding endurance of the films was found to be between 262 ± 2 to 301 ± 2 . The results are shown in Table 4.

Tensile strength

Tensile strength measures the ability of the film to withstand rupture. Study showed that an increase in tensile strength was observed with increase in polymer concentration. Polymers contain large number of chain of molecules and between these chains, homo polar bond and other types of bonds are possible. These bonds are either strong or feeble depending on the nature of polymer. According to the bonds formed force required to break the bonds and rupture the patch will differ. Tensile strength of the films was found to be between $1.27 \pm 0.021 \text{ kg/cm}^2$ to $2.45 \pm 0.0178 \text{ kg/cm}^2$. The results are shown in Table 4.

2. Percentage elongation

The Percentage elongation was found to be in the range of $12.5 \pm 4\%$ to $33.0 \pm 5\%$. The results are shown in Table 4.

In-vitro release studies

Dissolution study indicates the rate and extent of absorption. The *in-vitro* dissolution of Granisetron hydrochloride films were carried out using 900ml phosphate buffer of pH 6.8 using USP II basket type apparatus. *In-vitro* dissolution study for all the batches were performed for 3minutes. The results are shown in Table 5.

Table 5: In-vitro release studies of fast dissolving oral films of Granisetron hydrochloride

| Time (Sec) | Cumulative drug release | | | | | | | | | | | |
|------------|-------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | 48.927 | 45.327 | 41.727 | 39.927 | 54.654 | 52.527 | 50.563 | 47.618 | 54.163 | 53.836 | 52.2 | 50.890 |
| 60 | 55.281 | 51.081 | 45.081 | 44.127 | 63.436 | 61.445 | 58.009 | 56.863 | 65.154 | 64.445 | 65.536 | 61.172 |
| 90 | 60.544 | 56.181 | 51.681 | 48.954 | 74.345 | 72.763 | 64.881 | 60.681 | 74.318 | 72.736 | 70.663 | 69.163 |
| 120 | 65.072 | 59.045 | 54.681 | 52.445 | 85.009 | 82.827 | 74.399 | 72.245 | 85.936 | 83.236 | 80.809 | 78.627 |
| 150 | 69.436 | 64.77 | 57.6 | 54.681 | 90.409 | 87.136 | 84.627 | 78.327 | 92.372 | 91.963 | 90.136 | 87.681 |
| 180 | 75.299 | 69.272 | 60.981 | 58.74 | 99.899 | 95.809 | 93.954 | 91.636 | 99.872 | 95.290 | 93.409 | 91.418 |

Effect of CMC:

Dissolution studies of F1 to F4 revealed that the film containing CMC has release 75.29%, 69.27%, 60.98%, 58.74% respectively of drug in 180 seconds. The low release rate of CMC was due to high molecular weight of the polymer. Dissolution rate decrease with increase in molecular weight of polymer. The results are shown in Figure 6.




Figure 6: *In-vitro* release pattern of F1-F4 containing CMC(250,500,750&1000mg)

Effect of HPMC:

Dissolution studies of F5 to F8 revealed that the film containing HPMC E-15 has release 99.89%, 95.89%, 93.95%, 91.63% respectively of drug in 180 seconds. The results are shown in Figure 7.




Figure 7: *In-vitro* release pattern of F5-F8 containing HPMC(250,500,750&1000mg)

Effect of Pullulan:

Dissolution studies of F9 to F12 revealed that the film containing Pullulan has release 99.87%, 95.29%, 93.40%, 91.41% respectively of drug in 180 seconds. The results are shown and Figure 8.




Figure 8: *In-vitro* release pattern for F9-F12 containing Pullulan(500,750,1000&1250mg)

It was found that increase in the polymer concentration significantly decreased the drug release. The slow drug release mechanism for higher polymer concentration can be explained by reduction in permeability due to change in the morphology of the polymer. Increased polymer concentration may have provided the matrix with higher tortuosity and poor water porosity for diffusion of drug. Moreover, higher polymer concentration would have resulted in viscous environment of the system inhibiting movement of water into the matrix for easy diffusion of the drug into the surroundings.




Figure 9: *In-vitro* release of marketed Granisetron hydrochloride tablet




Figure10: Comparative study of *in-vitro* release pattern for F3,F7,F10 & marketed tablet

Table 7: *In-vitro* release studies of marketed Granisetron hydrochloride tablet

| Time (Sec) | %Cumulative drug released |
|------------|---------------------------|
| 0 | 0 |
| 30 | 2.126 |
| 60 | 2.709 |
| 90 | 3.257 |
| 120 | 3.708 |
| 150 | 4.256 |
| 180 | 4.995 |

Kinetic study

Kinetic model fitting was carried out for all the formulation F1 to F12 to understand the order and release pattern. The data was subjected to various kinetic equations and plotted according to zero order, first order, Higuchi and korsmeyr's equations. The first order plot was found to be fairly linear as indicated by their high regression value between (0.950 to 0.988). The data was fitted with Higuchi equation which yielded almost linear plots with their high regression co-efficient between (0.912 to 0.980) indicating the mechanism of drug release was diffusion. To know precisely whether fickian or non fickian diffusion existed the data was further plotted according to korsmeyer's peppas equation. The plot showed linearity with their 'n' values between (0.723 to 0.830). The observations showed that mechanism of drug release for all the formulation was non-fickian diffusion following first order release. Data is given in Table 6

Table 6: Kinetics study of fast dissolving oral films of Granisetron hydrochloride

| Formulation code | Zero Order | First order | Higuchi model | Korsmeyer-Peppas model | |
|------------------|----------------|----------------|----------------|------------------------|-------|
| | R ² | R ² | R ² | R ² | n |
| F1 | 0.719 | 0.968 | 0.927 | 0.937 | 0.830 |
| F2 | 0.717 | 0.965 | 0.925 | 0.938 | 0.824 |
| F3 | 0.694 | 0.974 | 0.914 | 0.936 | 0.802 |
| F4 | 0.691 | 0.955 | 0.912 | 0.936 | 0.793 |
| F5 | 0.827 | 0.979 | 0.978 | 0.953 | 0.821 |
| F6 | 0.821 | 0.950 | 0.977 | 0.953 | 0.791 |
| F7 | 0.844 | 0.978 | 0.976 | 0.954 | 0.723 |
| F8 | 0.845 | 0.974 | 0.973 | 0.955 | 0.803 |
| F9 | 0.827 | 0.953 | 0.980 | 0.954 | 0.825 |
| F10 | 0.812 | 0.976 | 0.974 | 0.952 | 0.817 |
| F11 | 0.819 | 0.984 | 0.976 | 0.953 | 0.795 |
| F12 | 0.819 | 0.988 | 0.976 | 0.953 | 0.761 |

Stability study

The selected formulation (F3, F7, and F10) was evaluated for stability studies which was stored at 40°C at 75%RH tested for 3month and were analyzed for physical appearance, disintegration time, drug content and *in-vitro* release rate at 1 month interval. It was found that films retained its physical appearance and there was no much significant change in the values of disintegration time, drug content and *in-vitro* release studies. The results are shown in Table 8-10.1 & Figure 11-13. This indicates that the oral films are stable at 40°C at 75%RH.

Stability studies

Table 8: Stability study data for F3 formulation

| Time in month | F3 formulation stored at 40°C/75%RH | | |
|---------------|-------------------------------------|---------------------|--------------|
| | Physical appearance | Disintegration time | Drug content |
| 1 | Transparent | 27 | 99.41 |
| 2 | Transparent | 26 | 99.23 |
| 3 | Transparent | 26 | 99.01 |

Table 8.1: % CDR during stability studies for F3 formulation

| Time(Sec) | 1 st Month | 2 nd Month | 3 rd Month |
|-----------|-----------------------|-----------------------|-----------------------|
| | F3 | F3 | F3 |
| 0 | 0 | 0 | 0 |
| 30 | 41.534 | 41.190 | 41.007 |
| 60 | 45.690 | 45.230 | 44.993 |
| 90 | 50.991 | 50.437 | 49.022 |
| 120 | 54.337 | 53.982 | 53.643 |
| 150 | 57.02 | 56.97 | 56.58 |
| 180 | 60.31 | 60.14 | 59.90 |

Table 9: Stability study data for F7 formulation

| Time in month | F7 formulation stored at 40°C/75%RH | | |
|---------------|-------------------------------------|---------------------|--------------|
| | Physical appearance | Disintegration time | Drug content |
| 1 | Transparent | 28 | 99.23 |
| 2 | Transparent | 27 | 99.15 |
| 3 | Transparent | 27 | 99.07 |

Table 9.1 %CDR during stability studies for F7 formulation

| Time(Sec) | 1 st Month | 2 nd Month | 3 rd Month |
|-----------|-----------------------|-----------------------|-----------------------|
| | F7 | F7 | F7 |
| 0 | 0 | 0 | 0 |
| 30 | 50.563 | 50.341 | 50.196 |
| 60 | 58.001 | 57.95 | 57.88 |
| 90 | 64.741 | 64.513 | 64.217 |
| 120 | 74.367 | 74.121 | 74.098 |
| 150 | 84.210 | 84.099 | 83.930 |
| 180 | 93.891 | 93.397 | 93.005 |

Table 10: Stability study data for F10 formulation

| Time in month | F10 formulation stored at 40°C/75%RH | | |
|---------------|--------------------------------------|---------------------|--------------|
| | Physical appearance | Disintegration time | Drug content |
| 1 | Transparent | 28 | 99.30 |
| 2 | Transparent | 27 | 99.21 |
| 3 | Transparent | 26 | 99.04 |

Table 10.1: %CDR during stability study for F10 formulation

| Time(Sec) | 1 st Month | 2 nd Month | 3 rd Month |
|-----------|-----------------------|-----------------------|-----------------------|
| | F10 | F10 | F10 |
| 0 | 0 | 0 | 0 |
| 30 | 53.836 | 53.661 | 53.310 |
| 60 | 64.430 | 64.194 | 63.971 |
| 90 | 72.561 | 72.191 | 72.146 |
| 120 | 83.129 | 83.010 | 82.95 |
| 150 | 91.910 | 91.730 | 91.231 |
| 180 | 95.117 | 95.054 | 94.989 |




Figure 11: %CDR during stability studies for F3 formulation




Figure 12: %CDR during stability studies for F7 formulation




Figure 13: %CDR during stability studies for F10 formulation

CONCLUSION

It can be concluded that fast dissolving oral films of Granisetron hydrochloride can be formulated using CMC, HPMC E-15 and Pullulan as a film forming polymer. Increase in polymer concentration was found to influence in all the aspects of physicochemical and mechanical properties of the films. The release pattern followed non-fickian diffusion with first order release. FTIR studies revealed that there is no interaction between drug and excipients. Therefore Granisetron hydrochloride can be conveniently administered orally in the form of films which can improve its bioavailability. Since the films showed promising results and there exist a scope for *in-vivo* evaluation using suitable animal models.

REFERENCES:

1. Alpesh R, Dharmendra S.P, Jignyasha A.R. Fast dissolving films as a newer venture in fast dissolving dosage forms. Int.J. of drug development & Res. 2010; 2(2):232-46.
2. Basani G, Subash VK, Guru S, Madhusudan RY. Overview on fast dissolving films. Int.J. of Pharmacy and Pharm Sci. 2010; 2(3):29-33.
3. Rajesh K, Rahul Ali.S, Arun Kumar.R. Fabrication and evaluation of telmisartan rapidly dissolving films. Int.J. Innovative Pharm Res. 2012; 3(2):220-27.
4. Renuka M, Avani A. Formulation and characterization of rapidly dissolving films of cetirizine hydrochloride using pullulan as a film forming agent. Ind. J. Pharm Educ Res. 2011; 45(1):72-77.
5. Sandeep.S, Nanda.A, Dhari.J. Formulation development and evaluation of oral fast dissolving anti-allergic film of levocetirizine di hydrochloride. J.Pharm.Sci.Res. 2011; 3(7):1322-25.
6. Vijaykumar.G, Ajaykumar.P, Satish KP, Karunasri.S, Raghavender K, Priya.P. Development and evaluation of fast dissolving film of Montelukast sodium. World J Medical Pharma Biological Sci. 2011; 1(1):06-12.
7. Seager.H, .Drug delivery products and zydis fast dissolving dosage forms. J.Pharm. Pharmacol. 1998; 50(4):375-82.
8. Suresh B, Borsadia, David.O, James L. Quick-Dissolving Films - A Novel Approach to Drug Delivery. Drug development and delivery. 2008; 3.
9. Ross and Wilson. Anatomy and physiology in health and illness, 9th edition edited by Anne Waugh and Allison Goraw published by Churchill Livingstone Edinburgh. 2001:289-93.

10. Narsamiha.R, Sindhu.K Kandhadi, Swapna D, Sushma.K, Swathi E. Formulation and evaluation of rapidly dissolving buccal patches. *Int.J. Pharma Biologic Sci* 2011; 1(3):145-59.
11. Arya.A, Chandra.A. Fast drug delivery system: A review. *Der pharmacia letter*. 2011; 2(2):350-61.
12. Arun A, Amrish. C, Vijay S, Kamla P. Fast dissolving oral films: An innovative drug delivery system and dosage form. *Int. J. Chem Tech Res*. 2010; 2(2):576-83.
13. Doijad RC, Manvi.F, V.Khalandar.K, S. Dada. A comparative study on mouth dissolving tablets of granisetron hydrochloride with different super disintegrant. *The internet. J. Pharmacol*. 2008; 5:(2).
14. Swany PV, Kinagi MB, Biradar S.S, Gada SN, Shilpa.H. Design and evaluation of buccoadhesive bilayer tablet of granistron hydrochloride. *Int.J. Pharm Sci Res*.2010; 1(8):104-10.
15. Kulkarni A.S, Deokule HA, Mane M.S, Ghadge D.M. Exploration of different polymers for use in the formulation of oral fast dissolving strips. *J C Pharm Res*. 2010; 2(1): 33-35.
16. Sumitha CH, Karuna SN, Divya B, Madhavi K, Vimal Kumar Varma M, Charbe NN. Taste masking of Ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating films. *Int.J. Chem Res*. 2009; 1(2):24-27.
17. Choudhary DR, VA Patel, HV Patel, Kundawala AJ. Formulation and evaluation of quick dissolving film of levocetirizine dihydrochloride. *Int.J. Pharm Technol* 2011; 3(1):1740-44.
18. Tadao T, Hirotaka Y, Naoki I, Kazuyuki H, Mayumi Y, Yasutomi k, Yoshinovi J. Preparation of fast dissolving oral thin film containing Dexamthasone. *Euro J Pharma Biopharma*. 2009; 73(3): 361-65.
19. Renuka S, Pavikh RH, Gohel MC, Soniwala MM. Development of taste masked film of Valdecoxib for oral use. *Ind. J. Pharm Sci*. 2007; 69(2):320-23.
20. Kulkarni PK, Dixit M, Gunashekava K, Shahnawaz A, Kulkarni A. Formulation and evaluation of mouth dissolving film containing Rofecoxib. *Int. Res J Pharm*.2011; 2(3):273-78.
21. Kunte S, Tandale P. Fast dissolving oral strips for the delivery of Verapamil. *J. Pharm and Bio allied Sci*. 2010; 2(4):325-28.

22. R.P. Dixit, S.P. Puthli. Oral Strip Technology: Overview and Future Potential. *J. Cont. Rele.* 2009; 139: 94-107.
23. Mashru RC, Sutariya VB, Sankalia MG, Parikh PP. Development and Evaluation of Fast Dissolving Film of Salbutamol Sulphate. *Ind Pharm.* 2005; 31(1):25–34.
24. Cilurzo F, Cupone IE, Minghetti P. Selmin F, Montanari L. Fast dissolving films made of Maltodextrins. *Eur .J. Pharm Biopharm.* 2008; 70(3):895–900.
25. Shweta K, Mayank B. Recent trends in the development of oral dissolving films. *Int. J.Pharmtech Res.* 2012; (2):725-33.
26. Renuka M, Avani A. Formulation and Characterization of Rapidly Dissolving Films of Cetirizine hydrochloride using Pullulan as a Film Forming Agent. *Ind .J. Pharm Educ.* 2011; 45(1):72-77.